Targeting P53 as a Future Strategy to Overcome Gemcitabine Resistance in Biliary Tract Cancers

Targeting P53 as a Future Strategy to Overcome Gemcitabine Resistance in Biliary Tract Cancers

Gemcitabine-based chemotherapy is the current standard treatment for biliary tract cancers (BTCs) and resistance to gemcitabine remains the clinical challenge. <i>TP53</i> mutation has been shown to be associated with poor clinicopathologic characteristics and survival in patients with B...

Full description

Bibliographic Details
Main Authors: Chiao-En Wu, Yi-Ru Pan, Chun-Nan Yeh, John Lunec
Format: Article
Language:English
Published: MDPI AG 2020-10-01
Series:Biomolecules
Subjects:
p53
gemcitabine resistance
biliary tract cancer
Online Access:https://www.mdpi.com/2218-273X/10/11/1474

Similar Items

Similar Items